



# Incidence, Microbiology, and Outcomes in Patients Hospitalized With Infective Endocarditis

**BACKGROUND:** Despite improvements in management, infective endocarditis remains associated with high mortality and morbidity. We describe temporal changes in the incidence, microbiology, and outcomes of infective endocarditis and the effect of changes in national antibiotic prophylaxis guidelines on incident infective endocarditis.

**METHODS:** Using a Scotland-wide, individual-level linkage approach, all patients hospitalized with infective endocarditis from 1990 to 2014 were identified and linked to national microbiology, prescribing, and morbidity and mortality datasets. Linked data were used to evaluate trends in the crude and age- and sex-adjusted incidence and outcomes of infective endocarditis hospitalizations. From 2008, microbiology data and associated outcomes adjusted for patient demographics and comorbidity were also analyzed. An interrupted time series analysis was performed to evaluate incidence before and after changes to national antibiotic prophylaxis guidelines.

**RESULTS:** There were 7638 hospitalizations (65±17 years, 51% females) with infective endocarditis. The estimated crude hospitalization rate increased from 5.3/100 000 (95% CI, 4.8–5.9) to 8.6/100 000 (95% CI, 8.1–9.1) between 1990 and 1995 but remained stable thereafter. There was no change in crude incidence following the 2008 change in antibiotic prophylaxis guidelines (relative risk of change 1.06 [95% CI, 0.94–1.20]). The incidence rate in patients >80 years of age doubled from 1990 to 2014 (17.7/100 000 [95% CI, 13.4–23.3] to 37.9/100 000 [95% CI, 31.5–45.5]). The predicted 1-year age- and comorbidity-adjusted case fatality rate for a 65-year-old patient decreased in women (27.3% [95% CI, 24.6–30.2] to 23.7% [95% CI, 21.1–26.6]) and men (30.7% [95% CI, 27.7–33.8] to 26.8% [95% CI, 24.0–29.7]) from 1990 to 2014. Blood culture data were available from 2008 (n=2267/7638, 30%), with positive blood cultures recorded in 42% (950/2267). *Staphylococcus* (403/950, 42.4%) and *streptococcus* (337/950, 35.5%) species were most common. *Staphylococcus aureus* and *enterococcus* had the highest 1-year mortality (adjusted odds ratio 4.34 [95% CI, 3.12–6.05] and 3.41 [95% CI, 2.04–5.70], respectively).

**CONCLUSIONS:** Despite changes in antibiotic prophylaxis guidelines, the crude incidence of infective endocarditis has remained stable. However, the incidence rate has doubled in the elderly. Positive blood cultures were observed in less than half of patients, with *Staphylococcus aureus* and *enterococcus* bacteremia associated with worse outcomes.

Anoop S.V. Shah<sup>1</sup>, MD, PhD\*  
David A. McAllister, MD\*  
Peter Gallacher, MD  
Federica Astengo, BSc  
Jesús Alberto Rodríguez Pérez, BSc  
Jennifer Hall, MD  
Kuan Ken Lee, MD  
Rong Bing, MD  
Atul Anand, MD  
Dilip Nathwani, MD  
Nicholas L. Mills, MD, PhD  
David E. Newby, MD, PhD  
Charis Marwick, MD, PhD  
Nicholas L. Cruden, MD, PhD

\*Drs Shah and McAllister contributed equally.

**Key Words:** antibiotic ■ antibiotic prophylaxis ■ incidence ■ infective endocarditis ■ mortality ■ outcomes

Sources of Funding, see page 2075

© 2020 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

<https://www.ahajournals.org/journal/circ>

## Clinical Perspective

### What Is New?

- Several studies have recently evaluated the changing epidemiology of infective endocarditis before and after guideline recommendations. These studies have predominantly studied the incidence, rather than the outcomes or microbiology, of infective endocarditis.
- Using a national, individual patient-level linkage approach, we describe the changing age- and sex-stratified incidence and outcomes of infective endocarditis in Scotland between 1990 and 2014.
- We further describe temporal changes in patient characteristics and microbiology based on positive blood cultures associated with infective endocarditis.

### What Are the Clinical Implications?

- The crude incidence rate of infective endocarditis hospitalizations increased from 1990 to 1995 but has remained relatively static thereafter with both short- and long-term adjusted case fatality rates showing a steady decrease over the past 25 years.
- The majority of patients with endocarditis in our cohort did not have positive blood cultures and in those with positive microbiology, staphylococcus and enterococcus conferred the highest risk for all-cause mortality.
- Changes in guidelines regarding antibiotic prophylaxis in the United Kingdom have not resulted in a significant change in incident cases of infective endocarditis.

Despite recent improvements in management, infective endocarditis remains associated with high morbidity and mortality.<sup>1,2</sup> Over the past few decades, several factors have affected both the incidence and outcomes of infective endocarditis. The population at risk of infective endocarditis has increased because of changes in population demographics, a rise in the use of implantable cardiac devices, an increase in the number of patients undergoing hemodialysis for end-stage renal failure, and a greater number of patients with congenital heart disease surviving to adulthood.<sup>3</sup> Changes in national guidelines regarding the use of antibiotic prophylaxis for prevention of infective endocarditis<sup>4,5</sup> have also been implicated in the apparent increase in the incidence of infective endocarditis.

Several studies have recently evaluated the changing epidemiology of infective endocarditis, predominantly incidence,<sup>6</sup> before and after guideline recommendations.<sup>4,7–10</sup> Fewer studies have evaluated microbiological causes and associated outcomes of endocarditis.<sup>11,12</sup> Using a national linkage approach, we describe the changing age- and sex-stratified incidence and outcomes of

infective endocarditis in Scotland over the past 25 years and the effect of changes in national guidelines on antibiotic prophylaxis. With the availability of a national microbiology surveillance registry from 2008 onward, we also describe the microbiology of infective endocarditis on the basis of positive blood culture data in a subgroup of infective endocarditis hospitalizations between 2008 and 2014.

## METHODS

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, these individual-level data are available through application to the National Health Service Public Health Scotland. Access to the data were approved by the National Health Service Scotland Public Benefit and Privacy Panel and in accordance with the Declaration of Helsinki. As the analysis used routinely collected and anonymized data, individual patient consent was not sought.

### Study Design and Data Sources

We conducted a consecutive retrospective individual patient linkage study across multiple national databases (Figure 1 in the Data Supplement). In brief, Scottish hospital discharge codes were used to identify patients hospitalized with infective endocarditis. All episodes for patients  $\geq 20$  years of age admitted between January 1, 1990, and December 31, 2014, identified as infective endocarditis were linked to the national hospitalization register (Scottish Morbidity Record 01) in Scotland. Incident cases of infective endocarditis identified from the national hospitalization register between January 1, 2008, and December 31, 2014, were also linked to positive blood culture data derived from individual patients derived through linkage with the national microbiology surveillance database (Electronic Communication of Surveillance in Scotland; Text I in the Data Supplement).

### Participants

Incident episodes of infective endocarditis were identified from hospital inpatient records using the *International Classification of Diseases 9 and 10* codes (Text II in the Data Supplement). On the basis of our validation exercise, only patients with a diagnostic code for endocarditis in the first 2 positions were included (Text III in the Data Supplement). A 5-year look-back period minimized the risk of recurrent episodes of infective endocarditis from being misclassified as incident cases (Text IV in the Data Supplement).

### Covariates

For each patient hospitalization, we extracted age at hospitalization, sex, comorbidity, and socioeconomic status. Socioeconomic status was assessed through a national area-based measure of deprivation, the Scottish Index of Multiple Deprivation (SIMD). The SIMD is measured in quintiles with the fifth quintile being least deprived. In brief, SIMD identifies small geographical regions (each region related to postal [zip] code and corresponding to approximately 750 residents)

of material deprivation based on information derived from 7 domains (income; employment; health; education, skills and training; geographic access to services; crime; and housing).<sup>13</sup> Scores from each domain (which are themselves weighted according to their relative importance) are combined into an overall score, which allows that area to be ranked. Scores and ranks based on SIMD have been used extensively in published epidemiological research from Scotland,<sup>14,15</sup> including guiding primary prevention in Scotland.<sup>16</sup> For our study, every patient enrolled in our cohort was assigned a SIMD quintile on the basis of their individual SIMD rank at the time of their index admission.

Patient comorbidities were defined using established *International Classification of Diseases* codes on the basis of previous hospitalizations and procedures using a 5-year look-back period. For every case of infective endocarditis during the 25-year period from 1990 until 2014, we extracted the following comorbidity data: (history of) myocardial infarction, cerebrovascular disease, heart failure hospitalization, implanted cardiac device, and cardiothoracic surgery (Text II in the Data Supplement). From 2009 onward, prescribing data were used to provide additional comorbidity classifications on the basis of dispensed drugs (Text V in the Data Supplement).

## Statistical Analysis

Baseline characteristics of all hospitalizations were summarized by 5 calendar year groups from 1990 to 2014 and in single calendar year groups from 2008 onward. Baseline characteristics were also summarized by blood culture status. Incident hospitalizations were summed by calendar year, age, and sex. Midyear population estimates for the general population in Scotland, stratified by age and sex, were obtained from the National Records of Scotland. For people without incident infective endocarditis, person-time not at risk (attributable to incident infective endocarditis events) was also summed by the same stratifying variables. Within the levels of these stratifying variables, person-time for people with no infective endocarditis was obtained by subtracting the infective endocarditis person-time from the midyear population estimates (Text IV in the Data Supplement). Outcomes consisted of mortality, stroke, heart failure hospitalization, and valve surgery at 30-days and 1-year following the index presentation.

## Modeling

Generalized additive models were used to estimate trends in incidence and outcomes of infective endocarditis. For incidence rates, log-link and Poisson error distribution were used with a scaling factor (quasi-Poisson) to allow for overdispersion. Incidence rates per year were generated for the whole population and stratified by sex and age. For outcomes, 1-year mortality was the primary outcome and year of admission as the primary explanatory variable adjusted for age, sex, comorbidity, and deprivation. For both estimation of trends in the incidence rates and outcomes of infective endocarditis, models were fitted using nonparametric smooth terms (penalized thin plate regression splines) for the year of admission. For the analysis of the association between 30-day and 1-year mortality and microbiology,

logistic regression models were constructed adjusted for age, sex, deprivation, and comorbidity.

An interrupted time series analysis<sup>17</sup> was used to evaluate the incident rates of infective endocarditis before (2001–2007) and after (2008–2014) the introduction of new antibiotic prophylaxis guidelines from the National Institute of Health and Care Excellence (Text VI in the Data Supplement).<sup>18</sup> A sensitivity analysis was also performed to evaluate the effect of restricting the cohort to the first diagnostic coding position. Statistical analysis was performed in R, version 3.5.1 (Vienna, Austria).

## RESULTS

Across 7513 individual patients, there were 7638 hospitalizations (mean age 65±17 years, 51% women) with incident infective endocarditis from 1990 to 2014 in Scotland (Table 1; Table I in the Data Supplement).

The estimated crude rate of hospitalization increased from 5.3 per 100 000 (95% CI, 4.8–5.9) to 8.6 per 100 000 (95% CI, 8.1–9.1) between 1990 and 1995 but remained stable thereafter with the incident rate in 2014 of 8.1 per 100 000 (95% CI, 7.5–8.9) (Figure 1A; Table II in the Data Supplement). Similar relative changes were seen in the incidence of infective endocarditis in our sensitivity analysis restricting the cohort to the first diagnostic code position (Figure II in the Data Supplement). Estimated rates comparing men and women also appeared similar up until 2003 but appeared to diverge thereafter (Figure III in the Data Supplement; Table II in the Data Supplement).

When stratified by age, patients >80 years showed a marked increase in the incidence of infective endocarditis rising from 17.7 per 100 000 (95% CI, 13.4–23.3) in 1990 to 37.9 per 100 000 (95% CI, 31.5–45.5) in 2014 (Figure 1B; Table III in the Data Supplement). In contrast, in the 60- to 79-year age group, the estimated rate was 11.5 per 100 000 (95% CI, 10.1–13.2) in 1990 peaking at 20.6 per 100 000 (95% CI, 19.2–22.0) in 1996 before steadily decreasing to 12.6 per 100 000 (95% CI, 11.1–14.3) in 2014. In the younger age groups, the incident rates of endocarditis appeared relatively unchanged (Figure 1B; Table III in the Data Supplement). There was no change in the incident rate of infective endocarditis following implementation of National Institute of Health and Care Excellence guidelines on antibiotic prophylaxis (relative risk of change, 1.06 [95% CI, 0.94–1.20],  $P=0.420$ ; Figure 2).

During the study period, 32% (2426/7638) of patients admitted to hospital with infective endocarditis died within 1 year of admission. Both age and sex influenced 1-year mortality, adjusted for deprivation and comorbidity (Table IV in the Data Supplement). Age-adjusted and sex-stratified predicted case fatality rates are shown in Figure IV and Table V in the Data Supplement. For a 65-year-old female, the predicted risk of 1-year

**Table 1. Baseline Characteristics and Outcomes in Patients Hospitalized With Infective Endocarditis, Stratified by 5-Year Calendar Groups**

Baseline Characteristics	Calendar Years in 5-Year Groups				
	1990–1994 (n=1379)	1995–1999 (n=1642)	2000–2004 (n=1464)	2005–2009 (n=1537)	2010–2014 (n=1616)
Age, y, mean (SD)	62.10 (17.25)	64.62 (16.34)	65.32 (17.59)	66.01 (16.92)	66.56 (17.96)
Women, n (%)	771 (55.9)	855 (52.1)	775 (52.9)	751 (48.9)	768 (47.5)
Scottish Index of Multiple Deprivation, n (%)					
Rank 1 (most deprived)	402 (29.4)	404 (24.7)	387 (26.6)	369 (24.1)	365 (22.7)
Rank 2	327 (23.9)	363 (22.2)	351 (24.1)	326 (21.3)	376 (23.4)
Rank 3	233 (17.1)	310 (19.0)	257 (17.7)	318 (20.7)	319 (19.9)
Rank 4	223 (16.3)	276 (16.9)	254 (17.5)	273 (17.8)	274 (17.1)
Rank 5 (least deprived)	181 (13.3)	282 (17.2)	205 (14.1)	248 (16.2)	271 (16.9)
Previous medical conditions and interventions, n (%)					
Myocardial infarction	59 (4.3)	89 (5.4)	60 (4.1)	65 (4.2)	80 (5.0)
Cerebrovascular disease	68 (4.9)	108 (6.6)	83 (5.7)	82 (5.3)	75 (4.6)
Heart failure hospitalization	220 (16.0)	315 (19.2)	251 (17.1)	206 (13.4)	173 (10.7)
Cardiac device	25 (1.8)	45 (2.7)	48 (3.3)	42 (2.7)	48 (3.0)
Prior cardiac valvular surgery	151 (10.9)	161 (9.8)	136 (9.3)	119 (7.7)	130 (8.0)
Outcomes at 30 days, n (%)					
All-cause death	196 (14.2)	233 (14.2)	231 (15.8)	198 (12.9)	223 (13.8)
Heart failure hospitalization	41 (3.0)	58 (3.5)	75 (5.1)	84 (5.5)	74 (4.6)
Subsequent valve surgery	64 (4.6)	77 (4.7)	66 (4.5)	73 (4.7)	86 (5.3)
Outcomes at 1 year, n (%)					
All-cause death	435 (31.5)	515 (31.4)	490 (33.5)	486 (31.6)	500 (30.9)
Heart failure hospitalization	189 (13.7)	215 (13.1)	177 (12.1)	191 (12.4)	158 (9.8)
Subsequent valve surgery	141 (10.2)	155 (9.4)	157 (10.7)	179 (11.6)	181 (11.2)


mortality reduced from 27.3% in 1990 (95% CI, 24.6–30.2) to 23.7% (95% CI, 21.0–26.6) in 2014. Similarly, for a 65-year-old male, the risk of 1-year death fell from 30.7% (95% CI, 27.7–33.8) to 26.8% (95% CI, 24.0–29.7). History of cerebrovascular disease (adjusted odds ratio [OR], 1.28 [95% CI, 1.07–1.49]), heart failure hospitalization (OR, 2.09 [95% CI, 1.96–2.22]), and deprivation (OR, 0.92 [95% CI, 0.88–0.95] per unit increment in rank; rank 1 assigned as being most deprived and rank 5 as least deprived) were also associated with a higher risk of death at 1 year.

Data on incident cases of infective endocarditis were available from 1990 to 2014. However, positive blood culture data were also available from 2008 until 2014. As such, the population with blood culture microbiology linkage consisted of 30% (2267/7638) of all hospitalizations (Table 2). Positive blood cultures were recorded in 42% (950/2267) of hospitalizations with the majority of the remainder being culture negative (defined as individuals in whom blood cultures yielded no organism or in whom no cultures were performed).

From our validation exercise, 12.5% of patients with a clinical diagnosis of infective endocarditis did not have blood cultures taken (Text III in the Data Supplement). At a national level, we could link patient level data to positive

microbiology only using the Electronic Communication of Surveillance in Scotland registry. As such, it was neither possible to determine what proportion of the remaining 1317 cases were associated with sterile blood cultures nor possible to determine what proportion did not have blood cultures performed. However, extrapolating from our validation data, where 87.5% of all cases had blood cultures performed, we assume that the majority of the 1317 cases also had blood cultures performed with a significant proportion yielding no growth.

*Staphylococcus* (403/950, 42.4%), *streptococcus* (337/950, 35.5%), and *enterococcus* (85/950, 8.9%) were the most common organisms identified (Figure V in the Data Supplement). The majority of staphylococci were *Staphylococcus aureus* (301/403, 74.7%). Across the years, positive microbiology rate increased from 34.7% in 2008 to 45.4% in 2014 (Figure VI in the Data Supplement). Several factors were associated with 30-day and 1-year mortality (Figure VII in the Data Supplement and Figure 3, respectively). Compared with patients without positive blood cultures, those with *Staphylococcus aureus* and *enterococcus* were at the highest risk of 1-year mortality (OR, 4.34 [95% CI, 3.12–6.05] and OR, 3.41 [95% CI, 2.04–5.70], respectively).



**Figure 1.** Estimated incidence rate per 100 000 in the population (A) and stratified by age groups (B).

Blue circles in **A** represent the absolute crude rates with the size of the circles proportional to the absolute count. The solid blue line represents the estimated incidence rate from generalized additive modeling using the Poisson distribution. The dashed blue lines represent the corresponding upper and lower 95% CI bounds.


In our sensitivity analysis restricting the cohort to the first diagnostic code position, positive blood cultures were identified in 63% (753/1195) of patients (Figure VIII in the Data Supplement). Similar to the primary analysis, those with *Staphylococcus aureus* and enterococcus were at the highest risk of 1-year mortality (OR, 2.23 [95% CI, 1.47–3.39] and OR, 1.89 [95% CI, 1.05 – 3.42], respectively), compared with patients without positive blood cultures (Figure IX in the Data Supplement).

## DISCUSSION

In this nationwide population cohort study using individual patient-level data linkage, we make several important observations. First, although the estimated overall crude incidence of infective endocarditis has remained relatively stable from 1995 onward, when stratified by age, there was a 2-fold increase in incidence in the elderly but either decreasing or static rates in younger patients. Second, the adjusted case fatality rate after endocarditis remains high but has declined over the past 25 years. After adjustment for age and

comorbidity, men had overall higher case fatality rates than women. Third, fewer than half of all patients had positive blood cultures, with the overall positive blood culture rate increasing from 35% in 2008 to slightly less than half in 2014. Where a causative organism was identified, staphylococcus and streptococcus were the most common species. Fourth, compared to patients with no positive blood cultures patients with *Staphylococcus aureus* or enterococcus bacteremia had the highest risk of death. Last, and perhaps of most clinical relevance, our analysis has shown that the 2008 change in antibiotic prophylaxis guidelines in the United Kingdom has not resulted in a significant rise in incident cases of infective endocarditis.

Population-based studies in endocarditis remain scarce with the majority of epidemiology extrapolated from hospital-based cohorts or cross-sectional studies.<sup>19,20</sup> Our dataset included cases of infective endocarditis over the past 25 years. Whereas we only had positive blood culture data for a fifth of this period, evaluating the overall period allowed us to investigate long-term trends in incidence of and outcomes after hospitalization with infective endocarditis. With the



**Figure 2.** Plot showing the observed incident rates per 100 000 by year of hospitalization (black dots), in relation to the introduction of national antibiotic prophylaxis guidelines.

The shaded gray box indicates introduction of National Institute of Health and Care Excellence antibiotic prophylaxis guidelines. The black line shows the predicted incident rate using the model described in Text VI in the Data Supplement, incorporating the change in guidelines from 2008 onward. The overlying red line shows the predicted incident rate assuming the counterfactual of no change in antibiotic prophylaxis guidelines in 2008.

exception of recent large population-based time-series analyses evaluating the temporal incidence of endocarditis in England<sup>4,21</sup> and the United States,<sup>7,22</sup> the majority of studies are limited by sample size, consisting of <1000 patients.<sup>20</sup> All of these studies are further limited by incomplete characterization of participant demographics and characteristics, including comorbidity, case-fatality rates, and microbiology. Using an established national linkage approach in Scotland,<sup>23,24</sup> we identified >7000 hospitalizations with a diagnosis of infective endocarditis and provide detailed individual patient-level information on baseline demographics, comorbidity burden, associated microbiology data, and subsequent case fatality rates.

As such, there are several strengths to our study. First, our approach ensured complete follow-up in those patients who remained resident in Scotland during the study period. Indeed, similar linkages have already been used to deliver randomized clinical trials<sup>23,25</sup> and cohort studies<sup>24</sup> in Scotland. Second, our cohort consisted of consecutive patients hospitalized with a diagnostic code for infective endocarditis, avoiding selection bias and

ensuring that our study population was representative. Third, unlike previous administrative data assets using diagnostic coding data to determine culture status,<sup>7,22</sup> which may not have been restricted to blood stream infections, we have used primary patient-level data from Scottish microbiology laboratories to ensure accurate recording of positive blood culture status. Fourth, using source clinical data, we validated the accuracy of the diagnostic coding including code position and microbiology data using data from local microbiology laboratory information systems (ensuring consistency with the national microbiology surveillance systems across Scotland).

Three relatively recent guideline updates have emerged from the National Institute of Health and Care Excellence<sup>18</sup> in the United Kingdom, the American Heart Association,<sup>26</sup> and the European Society of Cardiology.<sup>2</sup> These guidelines have recommended either complete or partial cessation of antibiotic prophylaxis in patients at moderate or high risk of infective endocarditis. Subsequent analyses evaluating the incidence of infective endocarditis have shown contrasting results. In England, a significant reduction in antibiotic

**Table 2.** Baseline Characteristics and Outcomes in Patients Hospitalized With Infective Endocarditis, by Blood Culture Status and Organism Identified


Baseline Characteristics	Culture Negative/ No Cultures (n=1317)	<i>Staphylococcus aureus</i> (n=301)	<i>Staphylococcus</i> (Coagulase Negative) (n=102)	<i>Streptococcus</i> (n=337)	<i>Enterococcus</i> (n=85)	Polymicrobial/ Other (n=125)
Age, y, mean (SD)	69.5 (16.9)	58.92 (19.09)	65.41 (14.95)	63.35 (17.39)	70.28 (13.06)	60.83 (19.22)
Women, n (%)	735 (55.8)	113 (37.5)	40 (39.2)	107 (31.8)	29 (34.1)	53 (42.4)
Scottish Index of Multiple Deprivation, n (%)						
Rank 1 (most deprived)	279 (21.3)	92 (30.7)	21 (20.6)	73 (21.7)	29 (34.1)	33 (26.6)
Rank 2	320 (24.5)	69 (23.0)	23 (22.5)	47 (14.0)	21 (24.7)	40 (32.3)
Rank 3	286 (21.9)	54 (18.0)	17 (16.7)	70 (20.8)	13 (15.3)	17 (13.7)
Rank 4	218 (16.7)	44 (14.7)	23 (22.5)	70 (20.8)	11 (12.9)	20 (16.1)
Rank 5 (least deprived)	205 (15.7)	41 (13.7)	18 (17.6)	76 (22.6)	11 (12.9)	14 (11.3)
Previous medical conditions and interventions, n (%)						
Myocardial infarction	68 (5.2)	12 (4.0)	8 (7.8)	17 (5.0)	<5	5 (4.0)
Cerebrovascular disease	62 (4.7)	13 (4.3)	7 (6.9)	15 (4.5)	9 (10.6)	6 (4.8)
Heart failure hospitalization	157 (11.9)	29 (9.6)	14 (13.7)	34 (10.1)	6 (7.1)	18 (14.4)
Cardiac device	27 (2.1)	12 (4.0)	8 (7.8)	<5	<5	6 (4.8)
Cardiac valve surgery	71 (5.4)	17 (5.6)	27 (26.5)	30 (8.9)	10 (11.8)	16 (12.8)
Chronic respiratory disease*	195 (19.1)	36 (14.8)	13 (15.5)	58 (20.7)	16 (22.5)	16 (16.2)
Diabetes mellitus*	133 (13.0)	35 (14.4)	22 (26.2)	30 (10.7)	11 (15.5)	18 (18.2)
Outcomes at 30 days, n (%)						
All-cause death	130 (9.9)	130 (9.9)	71 (23.6)	26 (25.5)	49 (14.5)	12 (14.1)
Heart failure hospitalization	78 (6.0)	6 (2.0)	<5	15 (4.5)	<5	7 (5.6)
Subsequent valve surgery	23 (1.8)	35 (11.6)	5 (4.9)	46 (13.6)	5 (5.9)	7 (5.6)
Outcomes at 1 year, n (%)						
All-cause death	336 (25.5)	133 (44.2)	46 (45.1)	99 (29.4)	43 (50.6)	41 (32.8)
Heart failure hospitalization	159 (12.1)	18 (6.0)	10 (9.8)	33 (9.8)	6 (7.1)	16 (12.8)
Subsequent valve surgery	87 (6.6)	54 (17.9)	18 (17.6)	85 (25.2)	9 (10.6)	19 (15.2)

\*Based on community prescribing (see [Text V in the Data Supplement](#)).

prescriptions and an apparent rise in the incidence of endocarditis was observed following the introduction of changes to National Institute of Health and Care Excellence guidelines.<sup>2,4</sup> Similar results were noted in a US-based population comparing incidence before and after changes to antibiotic prophylaxis guidelines in 2007.<sup>7</sup> In contrast, 3 studies from the United States showed no increase in incidence following changes to antibiotic prophylaxis guidelines.<sup>8,27,28</sup> These studies, however, were either limited in terms of cohort size<sup>8</sup> or evaluated incident rates over a shorter time frame following the change in guidelines.<sup>27</sup> Furthermore, small but well-characterized populations in the United States<sup>29</sup> and France<sup>10</sup> have also reported static incident rates. In our study, the crude incident rate of infective endocarditis increased in Scotland from 1990 until 1995 but remained relatively static thereafter, suggesting that changes to clinical guidelines regarding antibiotic prophylaxis were not associated with an adverse effect on the incidence of infective endocarditis in Scotland.

We observed an important interaction between age and rates of endocarditis. The incidence in patients older than 80 years of age increased 2-fold, while remaining static or decreasing in younger populations. This striking increase in the elderly is multifactorial and most likely reflects changes in the incidence of degenerative valvular heart disease, a rise in the number of patients surviving with multiple comorbidities, an increase in the provision of invasive therapeutic interventions, including implantable cardiac devices (pacemakers, defibrillators, closure devices, and percutaneous valve technology)<sup>30</sup> and hemodialysis,<sup>31</sup> and more extensive investigations<sup>32</sup> in frail, elderly patients.

We report important differences in the microbiology of patients with infective endocarditis compared with many studies in the existing literature. In our study, with linkage to a robust national microbiology laboratory blood culture dataset, no causative organism was identified in the majority (57%) of patients. In the published literature, culture-negative endocarditis varied from 15% to 60% across both hospital-based cohorts<sup>20,33</sup>



**Figure 3.** Forest plot showing odds ratio from logistic regression evaluating the association between all-cause mortality at 1 year and patient demographics, comorbidity, and microbiology.

and population registries that are based primarily on US populations.<sup>7,22,34</sup> Several reasons might explain our low culture-positive rates. First, we defined infective endocarditis using diagnostic coding. Although this is more sensitive and eliminated selection bias, it is possible that the lower rates of culture-positive cases reflect lower specificity by including some patients with lower probability of infective endocarditis. We validated the accuracy of the diagnostic coding using an in-depth health record review of nearly 400 cases. Restricting the patient population to the first 2 diagnostic positions gave an overall positive predictive value for definite or probable diagnosis of infective endocarditis of 88%. As such, case ascertainment bias caused by coding error is unlikely to have made a significant contribution. Second, from 2009 to 2012, 3 laboratories did not provide complete microbiology data for national linkage. These laboratories were small and served <1.5% of the Scottish population and would therefore have a negligible effect on the rates of positive blood cultures. Third, across most hospitalized cohorts of patients with infective endocarditis, cases were identified by the attending clinician.<sup>35</sup> A high culture-positive rate in these cohorts may therefore reflect selection bias toward patients with positive blood cultures.<sup>11</sup> Across population registry data, the culture-negative rates were higher<sup>7,22</sup> with similar rates to those observed in Scotland.<sup>34</sup> Fifth, across both population registries<sup>7,22</sup> and some hospital-based cohorts,<sup>36</sup> culture status was not restricted to blood cultures but also included tissue cultures including valves and serological tests, invariably increasing the rates of culture-positive diagnosis.<sup>36</sup> It is reassuring that, where positive blood

cultures were obtained in our cohort, streptococcus and staphylococcus were the most commonly identified pathogens, consistent with the wider literature.<sup>37,38</sup> Last, we noticed a relative rise of 16% in the proportion of patients with culture-positive infective endocarditis from 2008 to 2014. This observation likely reflects more judicious timing of administration of antibiotic treatment and ensuring blood cultures are taken prior to initiation of therapy; clinical practice that has been emphasized in recent international guidelines.<sup>39</sup>

Across the study cohort, crude temporal mortality rates at 1-year remained stable, ranging from 27% to 33%. However, after adjustment, we observed a steady reduction in mortality. A recent large US-based study showed a similar relationship with decreasing mortality over a similar time period<sup>22</sup> while others have shown little or no change in case fatality.<sup>4,40</sup> Positive microbiology was independently associated with poorer outcomes. *Staphylococcus aureus* bacteremia was independently associated with a 4-fold increased mortality rate at 30-days and 1-year. In contrast, the magnitude of association for enterococcus bacteremia changed from a 2-fold increased risk at 30-days to 3-fold increased risk at 1 year. This observation likely reflects a frailer and older population that is more susceptible to enterococcus bacteremia<sup>41,42</sup> and at higher risk of medium- to long-term mortality.<sup>43–45</sup>

## LIMITATIONS

There are several limitations to our study. First, index cases and comorbidity were defined using administrative



datasets, which are subject to inaccurate coding. However, we improved coding specificity for infective endocarditis using data from our validation work. To ensure a reasonable balance between specificity and sensitivity, we included all hospitalizations with a diagnostic code appearing in the first 2 (of 6) positions only. Restricting the population to the first diagnostic position markedly reduced the sensitivity for infective endocarditis in previous literature.<sup>22</sup> Second, for our validation exercise, the diagnosis of infective endocarditis was on the basis of a clinician documented diagnosis of infective endocarditis. Although we acknowledge that the Modified Duke Criteria represent the gold standard for defining cases of infective endocarditis,<sup>2</sup> unfortunately the majority of clinicians did not reference these criteria in clinical notes entered on electronic patient records. For example, the presence or absence of physical examination findings relevant to the minor criteria (eg, vascular or immunologic phenomena) were frequently not documented. After careful consideration of the impact of these missing data, and the potential for introducing significant bias, our research team elected to use a more pragmatic approach with true cases of infective endocarditis defined as those clinically documented and treated as infected endocarditis. Third, we could not differentiate patients with blood culture-negative infective endocarditis from those patients in whom blood cultures were not performed. From our validation work, we suspect that just more than 10% of all patients will fall into the latter category. Fourth, while we have attempted to address the majority of confounders, residual unmeasured confounding may have affected the trends observed in case fatality rates and the associations evaluating microbiology and risk of mortality.

## CONCLUSIONS

We report important temporal changes in patients with infective endocarditis in the Scottish population over the past 25 years. The crude incidence of infective endocarditis increased from 1990 to 1995 but has remained relatively static thereafter. It is of note that the incidence has increased 2-fold in the elderly. Both short- and long-term adjusted case fatality rates of infective endocarditis have shown a steady decrease over the past 25 years. Last, and of most interest, the majority of patients with infective endocarditis in our cohort did not have positive blood cultures. In those patients with positive microbiology, staphylococcus and enterococcus conferred the highest risk of all-cause mortality. Our data highlight that infective endocarditis remains a lethal condition, especially in the elderly. We also demonstrate the importance of microbiology data for prognostication, not only for in-hospital mortality but also for medium-term outcomes. As such, our data further

support the multidisciplinary integration of cardiology, microbiology and infectious disease teams as advocated by international guidelines to optimize diagnosis and patient care.<sup>2</sup>

## ARTICLE INFORMATION

Received November 15, 2019; accepted May 18, 2020.

This article was sent to Dr Ileana Piña, Guest Editor, for review by expert referees, editorial decision, and final disposition.

The Data Supplement is available at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.119.044913>.

## Correspondence

Dr Anoop S.V. Shah, British Heart Foundation/University Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh EH16 4SA, United Kingdom. Email [anoop.shah@ed.ac.uk](mailto:anoop.shah@ed.ac.uk)

## Affiliations

British Heart Foundation Centre for Cardiovascular Science (A.S.V.S., P.G., F.A., J.H., K.K.L., R.B., A.A., N.L.M., D.E.N.), Usher Institute of Population Health Sciences and Informatics (A.S.V.S., N.L.M.), University of Edinburgh, United Kingdom. Institute of Health and Wellbeing, University of Glasgow, United Kingdom (D.A.M., J.A.R.P.). Academic Health Sciences Partnership in Tayside, Ninewells Hospital and Medical School, Dundee, United Kingdom (D.N.). Population Health and Genomics, School of Medicine, University of Dundee, United Kingdom (C.M.). Edinburgh Heart Centre, Royal Infirmary of Edinburgh, United Kingdom (N.L.C.).

## Sources of Funding

This work was funded by the British Heart Foundation through an Intermediate Clinical Research Fellowship (FS/19/17/34172), Clinical Research Training Fellowship (FS/18/25/33454), Senior Clinical Research Fellowship (FS/16/14/32023), a Research Excellence Award (RE/18/5/34216), and Academy of Medical Sciences Starter Grants for Clinical Lecturers Scheme. Dr McAllister is supported by a Wellcome Trust Intermediate Clinical Fellowship (201492/Z/16/Z), and Dr Newby is supported by the British Heart Foundation (CH/09/002, RG/16/10/32375, RE/18/5/34216) and by a Wellcome Trust Senior Investigator Award (WT103782AIA).

## Disclosures

None.

## Supplemental Materials

Data Supplement Text I–VI  
Data Supplement Figures I–IX  
Data Supplement Tables I–VII  
References 46–48

## REFERENCES

1. Thuny F, Grisoli D, Collart F, Habib G, Raoult D. Management of infective endocarditis: challenges and perspectives. *Lancet*. 2012;379:965–975. doi: 10.1016/S0140-6736(11)60755-1
2. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J*. 2015;36:3075–3128. doi: 10.1093/eurheartj/ehv319
3. Carlton EW, Cullen L, Than M, Gamble J, Khattab A, Greaves K. A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin. *Heart*. 2015;101:1041–1046. doi: 10.1136/heartjnl-2014-307288

4. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. *Lancet*. 2015;385:1219-1228. doi: 10.1016/S0140-6736(14)62007-9
5. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, et al; American Heart Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *J Am Dent Assoc*. 2008;139 Suppl:35-245. doi: 10.14219/jada.archive.2008.0346
6. Selton-Suty C, Célarid M, Le Moing V, Doco-Lecompte T, Chirouze C, lung B, Strady C, Revest M, Vandenesch F, Bouvet A, et al; AEPEI Study Group. Preeminence of *Staphylococcus aureus* in infective endocarditis: a 1-year population-based survey. *Clin Infect Dis*. 2012;54:1230-1239. doi: 10.1093/cid/cis199
7. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, Hirsch GA, Mehta JL. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol*. 2015;65:2070-2076. doi: 10.1016/j.jacc.2015.03.518
8. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, Wilson WR, Baddour LM; Mayo Cardiovascular Infections Study Group. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. *Circulation*. 2012;126:60-64. doi: 10.1161/CIRCULATIONAHA.112.095281
9. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, Shah SS. Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. *Am Heart J*. 2012;163:894-899. doi: 10.1016/j.ahj.2012.03.002
10. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, Doco-Lecompte T, Celard M, Poyart C, Strady C, et al; AEPEI Study Group. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. *J Am Coll Cardiol*. 2012;59:1968-1976. doi: 10.1016/j.jacc.2012.02.029
11. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis—Prospective Cohort Study. *Arch Intern Med*. 2009;169:463-473. doi: 10.1001/archinternmed.2008.603
12. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, et al; ICE Investigators. *Staphylococcus aureus* endocarditis: a consequence of medical progress. *JAMA*. 2005;293:3012-3021. doi: 10.1001/jama.293.24.3012
13. Scottish Government. The Scottish Index of Multiple Deprivation (SIMD) 2020. Accessed January 20, 2020. <https://www.gov.scot/publications/scottish-index-multiple-deprivation-2020/pages/1/>
14. McAllister DA, Read SH, Kerssens J, Livingstone S, McGurnaghan S, Jhund P, Petrie J, Sattar N, Fischbacher C, Kristensen SL, et al. Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. *Circulation*. 2018;138:2774-2786. doi: 10.1161/CIRCULATIONAHA.118.034986
15. O'Flaherty M, Bishop J, Redpath A, McLaughlin T, Murphy D, Chalmers J, Capewell S. Coronary heart disease mortality among young adults in Scotland in relation to social inequalities: time trend study. *BMJ*. 2009;339:b2613. doi: 10.1136/bmj.b2613
16. Woodward M, Brindle P, Tunstall-Pedoe H; SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart*. 2007;93:172-176. doi: 10.1136/hrt.2006.108167
17. Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. *Int J Epidemiol*. 2017;46:348-355. doi: 10.1093/ije/dyw098
18. National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures 2008. NICE Clinical Guideline No 64. Updated 2016. Accessed March 23, 2020. <https://www.nice.org.uk/guidance/cg64/chapter/Recommendations>
19. Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, Wilson WR, Baddour LM. A systematic review of population-based studies of infective endocarditis. *Chest*. 2007;132:1025-1035. doi: 10.1378/chest.06-2048
20. Slipczuk L, Codolosa JN, Davila CD, Romero-Corral A, Yun J, Pressman GS, Figueredo VM. Infective endocarditis epidemiology over five decades: a systematic review. *PLoS One*. 2013;8:e82665. doi: 10.1371/journal.pone.0082665
21. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, Lockhart PB. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. *BMJ*. 2011;342:d2392. doi: 10.1136/bmj.d2392
22. Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York state, 1998-2013. *JAMA*. 2017;317:1652-1660. doi: 10.1001/jama.2017.4287
23. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, Sandeman D, Stables CL, Adamson PD, Andrews JPM, et al; High-STEACS Investigators. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet*. 2018;392:919-928. doi: 10.1016/S0140-6736(18)31923-8
24. Shah ASV, Sandoval Y, Noaman A, Sexter A, Vaswani A, Smith SW, Gibbins M, Griffiths M, Chapman AR, Strachan FE, et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. *BMJ*. 2017;359:j4788. doi: 10.1136/bmj.j4788
25. Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S et al. Coronary CT angiography and 5-year risk of myocardial infarction. *N Engl J Med*. 2018;379:924-933.
26. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007;116:1736-1754. doi: 10.1161/CIRCULATIONAHA.106.183095
27. Rogers AM, Schiller NB. Impact of the first nine months of revised infective endocarditis prophylaxis guidelines at a university hospital: so far so good. *J Am Soc Echocardiogr*. 2008;21:775. doi: 10.1016/j.echo.2008.04.001
28. Bickdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends in hospitalization rates and outcomes of endocarditis among Medicare beneficiaries. *J Am Coll Cardiol*. 2013;62:2217-2226. doi: 10.1016/j.jacc.2013.07.071
29. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, Steckelberg JM, Wilson WR, Baddour LM. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN. *Am Heart J*. 2015;170:830-836. doi: 10.1016/j.ahj.2015.07.007
30. Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MS. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. *Open Heart*. 2014;1:e000177. doi: 10.1136/openhrt-2014-000177
31. Dhawan VK. Infective endocarditis in elderly patients. *Clin Infect Dis*. 2002;34:806-812. doi: 10.1086/339045
32. Jenniskens K, de Groot JAH, Reitsma JB, Moons KGM, Hooft L, Naaktgeboren CA. Overdiagnosis across medical disciplines: a scoping review. *BMJ Open*. 2017;7:e018448. doi: 10.1136/bmjopen-2017-018448
33. Letaief A, Boughzala E, Kaabia N, Ernez S, Abid F, Ben Chaabane T, Ben Jemaa M, Boujnah R, Chakroun M, Daoud M, et al. Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. *Int J Infect Dis*. 2007;11:430-433. doi: 10.1016/j.ijid.2006.10.006
34. Kadri AN, Wilner B, Hernandez AV, Nakhoul G, Chahine J, Griffin B, Pettersson G, Grimm R, Navia J, Gordon S, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. *J Am Heart Assoc*. 2019;8:e012969. doi: 10.1161/JAHA.119.012969
35. Issa VS, Fabri J Jr, Pomerantzeff PM, Grinberg M, Pereira-Barreto AC, Mansur AJ. Duration of symptoms in patients with infective endocarditis. *Int J Cardiol*. 2003;89:63-70. doi: 10.1016/s0167-5273(02)00424-2

36. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, Casalta JP, Danchin N, Delahaye F, Etienne J, et al; Association pour l'Etude et la Prévention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA*. 2002;288:75–81. doi: 10.1001/jama.288.1.75
37. Cahill TJ, Prendergast BD. Infective endocarditis. *Lancet*. 2016;387:882–893. doi: 10.1016/S0140-6736(15)00067-7
38. Que YA, Moreillon P. Infective endocarditis. *Nat Rev Cardiol*. 2011;8:322–336. doi: 10.1038/nrcardio.2011.43
39. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017;43:304–377. doi: 10.1007/s00134-017-4683-6
40. Cuervo G, Rombauts A, Caballero Q, Grau I, Pujol M, Ardanuy C, Berbel D, Gudiol C, Sánchez-Salado JC, Ruiz-Majoral A, et al. Twenty-year secular trends in infective endocarditis in a teaching hospital. *Open Forum Infect Dis*. 2018;5:ofy183. doi: 10.1093/ofid/ofy183
41. Linden PK, Miller CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. *Diagn Microbiol Infect Dis*. 1999;33:113–120. doi: 10.1016/s0732-8893(98)00148-5
42. Suppli M, Aabenhus R, Harboe ZB, Andersen LP, Tvede M, Jensen JU. Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. *Clin Microbiol Infect*. 2011;17:1078–1083. doi: 10.1111/j.1469-0691.2010.03394.x
43. Schönheyder HC, Sjøgaard M. Hospitalsrørvet bakteræmi og fungæmi: Regionale data med nationale perspektiver. *Ugeskr Laeger*. 2007;169:4175–4179.
44. Bar K, Wisplinghoff H, Wenzel RP, Bearman GM, Edmond MB. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infections due to enterococci. *BMC Infect Dis*. 2006;6:145. doi: 10.1186/1471-2334-6-145
45. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, Lyons RW. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. *Medicine (Baltimore)*. 1995;74:191–200. doi: 10.1097/00005792-199507000-00003
46. Bennie M, Malcolm W, Marwick CA, Kavanagh K, Sneddon J, Nathwani D. Building a national Infection Intelligence Platform to improve antimicrobial stewardship and drive better patient outcomes: the Scottish experience. *J Antimicrob Chemother*. 2017;72:2938–2942. doi: 10.1093/jac/dkx229
47. NHS National Services Scotland. Infection Intelligence Platform (IIP)- High level guide to IIP component datasets held by NHS National Services Scotland. 2014. Accessed March 18, 2020. <https://www.isdscotland.org/Health-Topics/Health-and-Social-Community-Care/Infection-Intelligence-Platform/Data/June-2014-Guide-to-IIP-Data.pdf>
48. Scottish Government. Scottish Management of Antimicrobial Resistance Action Plan 2014-2018. 2014. Accessed March 2, 2020. <http://www.gov.scot/Publications/2014/07/9192>